Juno Therapeutics Inc (NASDAQ:JUNO) announced that clinical data from a chimeric antigen receptor (CAR) T cell product candidate, JCAR014, demonstrated encouraging clinical responses in patients …
Juno Therapeutics Inc (NASDAQ:JUNO), a leading biopharmaceutical company focused on re-engaging the body’s immune system to revolutionize the treatment of cancer, and Editas …
